for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

iCAD Inc

ICAD.OQ

Latest Trade

7.45USD

Change

0.05(+0.68%)

Volume

20,751

Today's Range

7.10

 - 

7.60

52 Week Range

2.50

 - 

7.64

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.40
Open
7.46
Volume
20,751
3M AVG Volume
2.22
Today's High
7.60
Today's Low
7.10
52 Week High
7.64
52 Week Low
2.50
Shares Out (MIL)
19.26
Market Cap (MIL)
142.54
Forward P/E
-19.10
Dividend (Yield %)
--

Latest Developments

More

Icad Reports Q2 GAAP Loss Per Share $0.20

iCAD Announces Pricing Of Public Offering Of Common Stock

Icad Announces Proposed Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About iCAD Inc

iCAD, Inc. is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). The Detection segment consists of its advanced image analysis and workflow products, and the Therapy segment consists of its radiation therapy products. The Company sells its products through its direct sales organization, as well as through various original equipment manufacturer partners, distributors and resellers. It develops and markets computer-aided detection (CAD) solutions for digital and film-based mammography systems. Its Axxent SPX Controller includes an optimized skin treatment arm customized for compatibility in confined patient treatment rooms in physician office-based facilities.

Industry

Medical Equipment & Supplies

Contact Info

98 Spit Brook Rd Ste 100

+1.603.8825200

http://www.icadmed.com

Executive Leadership

Michael S. Klein

Executive Chairman of the Board, Chief Executive Officer

Stacey M. Stevens

President

R. Scott Areglado

Chief Financial Officer, Vice President, Controller

Jonathan Go

Chief Technology Officer

Rakesh Patel

Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.630

2017

-0.610

2018

-0.380

2019(E)

-0.390
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.23
Price To Book (MRQ)
13.08
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
154.24
LT Debt To Equity (MRQ)
133.46
Return on Investment (TTM)
-55.92
Return on Equity (TTM)
-34.86

Latest News

BRIEF-iCad Reports Q1 GAAP Loss Per Share $0.20

* Q1 REVENUE FELL 7 PERCENT TO $6.3 MILLION Source text for Eikon: Further company coverage:

BRIEF-Icad Q4 Gaap Loss Per Share $0.26

* ICAD REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

BRIEF-iCAD Expects To Reduce About 18 Pct Of Workforce Across Skin Subscription Business

* ICAD INC SAYS CO EXPECTS TO REDUCE HEADCOUNT ACROSS SKIN SUBSCRIPTION BUSINESS BY ABOUT 21 EMPLOYEES OR 18% OF THE WORKFORCE- SEC FILING

BRIEF-ICAD reports Q3 GAAP loss per share $0.42

* Q3 revenue rose 17 percent to $7.0 million Source text for Eikon: Further company coverage:

BRIEF-ICAD Inc ‍announces approval of Xoft Axxent balloon applicators by China FDA

* ICAD Inc - announces approval of Xoft Axxent balloon applicators by China Food & Drug Administration for treatment of early-stage breast cancer Source text for Eikon: Further company coverage:

BRIEF-ICAD reports Q2 loss per share $0.16

* iCAD reports second quarter 2017 financial results and announces $13 million credit facility with silicon valley bank

BRIEF-iCAD provides positive eBx system data in skin cancer patients

* Icad announces positive study results comparing use of company’s xoft® axxent® electronic brachytherapy (ebx®) system® to mohs surgery in treatment of early-stage non-melanoma skin cancer Source text for Eikon: Further company coverage:

BRIEF-Icad Q1 revenue rose 12.5 percent to $6.8 million

* Q1 adjusted non-GAAP loss per share $0.18 Source text for Eikon: Further company coverage:

BRIEF-Harbert Discovery Fund reports 5.01 percent stake in Icad

* Harbert Discovery Fund LP reports 5.01 percent stake in Icad Inc as of Nov. 7 - SEC filing

BRIEF-ICAD Q3 adjusted non-gaap loss per share $0.16

* Says company is not providing financial guidance at this time

BRIEF-iCAD appoints Scott Areglado as interim CFO

* Says appointed R Scott Areglado to serve as interim chief financial officer, interim treasurer and interim secretary - SEC filing Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up